Immunogenicity of panitumumab in combination chemotherapy clinical trials

BACKGROUND: Panitumumab is a fully human antibody against the epidermal growth factor receptor that is indicated for the treatment of metastatic colorectal cancer (mCRC) after disease progression on standard chemotherapy. The purpose of this analysis was to examine the immunogenicity of panitumumab...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Weeraratne, Dohan, Chen, Alin, Pennucci, Jason J, Wu, Chi-Yuan, Zhang, Kathy, Wright, Jacqueline, Pérez-Ruixo, Juan José, Yang, Bing-Bing, Kaliyaperumal, Arunan, Gupta, Shalini, Swanson, Steven J, Chirmule, Narendra, Starcevic, Marta
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2011
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3231982/
https://ncbi.nlm.nih.gov/pubmed/22070868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6904-11-17
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires